Miyad Movassaghi, MD
Urology · Raleigh, NCNPI 1407352677
Payments from drug & device makers
Across 78 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$405
- Sumitomo Pharma America, Inc.$300
- Johnson & Johnson$211
- Ambu Inc.$160
- Teleflex LLC$148
- Endo USA, Inc.$137
- plus $984 from 18 others
What the payments were for
- Speaking & faculty fees$151%
- Food & beverage$2,32999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 3 | $405 |
| Sumitomo Pharma America, Inc. | 13 | $300 |
| Johnson & Johnson | 8 | $211 |
| Ambu Inc. | 2 | $160 |
| Teleflex LLC | 5 | $148 |
| Endo USA, Inc. | 7 | $137 |
| Dendreon Pharmaceuticals LLC | 5 | $131 |
| Urogen Pharma, Inc. | 3 | $96 |
| Pfizer | 4 | $92 |
| Myriad Genetic Laboratories, Inc. | 4 | $74 |
| Bayer | 3 | $71 |
| Boston Scientific | 1 | $70 |
| Merck | 3 | $70 |
| Coloplast | 2 | $57 |
| Novartis | 2 | $55 |
| AbbVie | 2 | $51 |
| Olympus America Inc. | 2 | $44 |
| Progenics Pharmaceuticals, Inc. | 2 | $35 |
| Medtronic | 2 | $31 |
| Angiodynamics, Inc. | 1 | $29 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Immunitybio, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| BD | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,344 in reported general payments places this provider in the 45th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 18 | $11,358 |
| Estradiol | 15 | $1,101 |
| Trospium Chloride | 12 | $469 |
| Tamsulosin Hcl | 52 | $454 |
| Cefdinir | 16 | $251 |
| Cephalexin | 12 | $88 |
| Oxycodone Hcl | 17 | $43 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $38 |
| Levofloxacin | 20 | $36 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Other urology in Raleigh
- John KasparRaleigh$1.1M
- Mark JalkutRaleigh$516K
- Aaron LentzRaleigh$371K
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- Scott MacdiarmidGreensboro$882K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.